---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023234"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:48:24.100728+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reneo reports Q3 net loss $13.0M, >80% enrolled in pivotal STRIDE study

## Summary
- Net loss of $13.0M ($0.53 per share) vs $12.7M ($0.52) in Q3 2021.
- Cash, equivalents & short-term investments total $116M as of Sept 30, 2022.
- Over 80% enrollment in pivotal STRIDE study for PMM with mtDNA defects; topline data expected Q4 2023.
- Positive Phase 1b results in LC-FAOD patients; planning Phase 2 study.
- FDA and EMA confirmed positive data from STRIDE/STRIDE AHEAD could support registration.

## SEC filing metadata
- accession: 0000950170-22-023234
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017022023234/0000950170-22-023234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017022023234/rphm-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023234
- JSON: https://secwatch.observer/filing/0000950170-22-023234.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023234.txt

## Key facts
- Earnings Releases
  OnKure Therapeutics, Inc. reported the three months ended September 30, 2022 results: net income $13.0 million, EPS $0.53 per share.
  - Period: the three months ended September 30, 2022
  - Net income: $13.0 million
  - EPS: $0.53 per share
  - Result: reported results
  source text: The Company reported a net loss of $13.0 million, or $0.53 per share, for the three months ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000095017022023234/0000950170-22-023234-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.